Logo image of GRCL

GRACELL BIOTECHNOLOGIES-ADR (GRCL) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:GRCL - US38406L1035 - ADR

10.25 USD
+0.01 (+0.05%)
Last: 2/21/2024, 8:00:01 PM
10.25 USD
0 (0%)
After Hours: 2/21/2024, 8:00:01 PM
Fundamental Rating

2

GRCL gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 533 industry peers in the Biotechnology industry. The financial health of GRCL is average, but there are quite some concerns on its profitability. GRCL does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year GRCL has reported negative net income.
In the past year GRCL has reported a negative cash flow from operations.
GRCL had negative earnings in each of the past 5 years.
In the past 5 years GRCL always reported negative operating cash flow.
GRCL Yearly Net Income VS EBIT VS OCF VS FCFGRCL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 -200M -400M -600M

1.2 Ratios

GRCL has a Return On Assets (-43.64%) which is in line with its industry peers.
The Return On Equity of GRCL (-52.90%) is better than 64.77% of its industry peers.
Industry RankSector Rank
ROA -43.64%
ROE -52.9%
ROIC N/A
ROA(3y)-29.05%
ROA(5y)-37.01%
ROE(3y)-34.16%
ROE(5y)-644.48%
ROIC(3y)N/A
ROIC(5y)N/A
GRCL Yearly ROA, ROE, ROICGRCL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 -1K -2K -3K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for GRCL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GRCL Yearly Profit, Operating, Gross MarginsGRCL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 -20K -40K -60K -80K -100K

More info and screens

5

2. Health

2.1 Basic Checks

GRCL does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, GRCL has about the same amount of shares outstanding.
The debt/assets ratio for GRCL is higher compared to a year ago.
GRCL Yearly Shares OutstandingGRCL Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 20M 40M 60M 80M
GRCL Yearly Total Debt VS Total AssetsGRCL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 500M 1B 1.5B 2B

2.2 Solvency

An Altman-Z score of 15.19 indicates that GRCL is not in any danger for bankruptcy at the moment.
The Altman-Z score of GRCL (15.19) is better than 88.25% of its industry peers.
GRCL has a Debt/Equity ratio of 0.12. This is a healthy value indicating a solid balance between debt and equity.
GRCL's Debt to Equity ratio of 0.12 is on the low side compared to the rest of the industry. GRCL is outperformed by 67.28% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF N/A
Altman-Z 15.19
ROIC/WACCN/A
WACC9.48%
GRCL Yearly LT Debt VS Equity VS FCFGRCL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 0 500M -500M 1B 1.5B

2.3 Liquidity

GRCL has a Current Ratio of 6.44. This indicates that GRCL is financially healthy and has no problem in meeting its short term obligations.
GRCL's Current ratio of 6.44 is fine compared to the rest of the industry. GRCL outperforms 61.74% of its industry peers.
GRCL has a Quick Ratio of 6.44. This indicates that GRCL is financially healthy and has no problem in meeting its short term obligations.
GRCL has a Quick ratio of 6.44. This is in the better half of the industry: GRCL outperforms 62.58% of its industry peers.
Industry RankSector Rank
Current Ratio 6.44
Quick Ratio 6.44
GRCL Yearly Current Assets VS Current LiabilitesGRCL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 500M 1B 1.5B

More info and screens

0

3. Growth

3.1 Past

GRCL shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -4.00%.
GRCL shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)-4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -18.88% on average over the next years. This is quite bad
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y29.78%
EPS Next 2Y25.47%
EPS Next 3Y3.89%
EPS Next 5Y-18.88%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GRCL Yearly Revenue VS EstimatesGRCL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2026 2027 2028 2029 2030 1B 2B 3B 4B
GRCL Yearly EPS VS EstimatesGRCL Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

GRCL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year GRCL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GRCL Price Earnings VS Forward Price EarningsGRCL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 100 -100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GRCL Per share dataGRCL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.47%
EPS Next 3Y3.89%

More info and screens

0

5. Dividend

5.1 Amount

GRCL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GRACELL BIOTECHNOLOGIES-ADR

NASDAQ:GRCL (2/21/2024, 8:00:01 PM)

After market: 10.25 0 (0%)

10.25

+0.01 (+0.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2023-11-13/bmo
Earnings (Next)03-11 2024-03-11/amc
Inst Owners0.05%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap989.87M
Revenue(TTM)N/A
Net Income(TTM)-601.28M
Analysts78.67
Price Target10.76 (4.98%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)19.8%
Min EPS beat(2)13.13%
Max EPS beat(2)26.47%
EPS beat(4)2
Avg EPS beat(4)-34.87%
Min EPS beat(4)-136.32%
Max EPS beat(4)26.47%
EPS beat(8)3
Avg EPS beat(8)-77.59%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.31%
PT rev (3m)-9.94%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)22.51%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 6.27
P/tB 6.27
EV/EBITDA N/A
EPS(TTM)-0.18
EYN/A
EPS(NY)-0.08
Fwd EYN/A
FCF(TTM)-0.85
FCFYN/A
OCF(TTM)-0.81
OCFYN/A
SpS0
BVpS1.64
TBVpS1.64
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -43.64%
ROE -52.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-29.05%
ROA(5y)-37.01%
ROE(3y)-34.16%
ROE(5y)-644.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 66.93%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.44
Quick Ratio 6.44
Altman-Z 15.19
F-Score1
WACC9.48%
ROIC/WACCN/A
Cap/Depr(3y)192.19%
Cap/Depr(5y)411.73%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y29.78%
EPS Next 2Y25.47%
EPS Next 3Y3.89%
EPS Next 5Y-18.88%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-8.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year5.22%
EBIT Next 3Y-7.21%
EBIT Next 5YN/A
FCF growth 1Y-46.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-58.48%
OCF growth 3YN/A
OCF growth 5YN/A

GRACELL BIOTECHNOLOGIES-ADR / GRCL FAQ

What is the ChartMill fundamental rating of GRACELL BIOTECHNOLOGIES-ADR (GRCL) stock?

ChartMill assigns a fundamental rating of 2 / 10 to GRCL.


Can you provide the valuation status for GRACELL BIOTECHNOLOGIES-ADR?

ChartMill assigns a valuation rating of 0 / 10 to GRACELL BIOTECHNOLOGIES-ADR (GRCL). This can be considered as Overvalued.


What is the profitability of GRCL stock?

GRACELL BIOTECHNOLOGIES-ADR (GRCL) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for GRCL stock?

The Earnings per Share (EPS) of GRACELL BIOTECHNOLOGIES-ADR (GRCL) is expected to grow by 29.78% in the next year.